 "Brokers trade at their computer terminals at a stock brokerage firm in Mumbai. Photo: Reuters")
Cadila Healthcare dipped 8% to Rs 374 on the BSE in intra-day after the company reported 29% year on year (YoY) drop in its consolidated net profit at Rs 338 crore for the quarter ended September 30, 2016 (Q2FY17). Analysts on an average had expected profit of Rs 380 crore.
The pharmaceutical company had profit of Rs 416 crore in the same quarter year ago.
Total income from operations remain flat at Rs 2,404 crore in Q2FY17 against Rs 2,395 crore in the corresponding quarter of previous fiscal.
At 01:26 PM, the stock was down 6% at Rs 382 on BSE, as compared to 0.72% fall in S&P BSE Sensex. A combined 2.39 million shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on BSE and NSE.
The pharmaceutical company had profit of Rs 416 crore in the same quarter year ago.
Total income from operations remain flat at Rs 2,404 crore in Q2FY17 against Rs 2,395 crore in the corresponding quarter of previous fiscal.
At 01:26 PM, the stock was down 6% at Rs 382 on BSE, as compared to 0.72% fall in S&P BSE Sensex. A combined 2.39 million shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on BSE and NSE.
